Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up to ...

India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal ...

to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million.

to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million. Coherus ...

Private equity activity in healthcare remained resilient with 42 deals worth $562 million, just shy of last quarter’s $603 ...

Election Commission data shows growth in political donations, with BJP receiving majority; corporate trusts dominate ...

Dr. Kiran Mahasuar, Asst Professor at IMT Ghaziabad, writes why branded generics may still dominate volumes, but the real ...

Shareholders have approved the sale of Coherus’s UDENYCA franchise to Intas Pharmaceuticals, a significant move in the company’s strategic shift towards focusing on oncology. The proceeds from ...

Shareholders have approved the sale of the UDENYCA franchise to Intas Pharmaceuticals, which is a significant step in Coherus’s strategic shift towards enhancing its oncology portfolio.

DelveInsight's "Uterine Sarcoma Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth ...